---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-013103"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:56:57.297472+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M

## Summary
- PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.
- Preliminary Q3 2025 ZYNLONTA net product revenue approximately $15.8M.
- Cash and equivalents $234.7M as of Sep 30; pro forma $292.3M after PIPE net proceeds (~$57.6M).
- PIPE led by TCGX with Redmile Group and other existing investors; Jefferies acted as placement agent.
- Net proceeds to fund ZYNLONTA commercial expansion, strengthen balance sheet, and working capital.

## SEC filing metadata
- accession: 0000950103-25-013103
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/0000950103-25-013103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010325013103/dp235779_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-013103
- JSON: https://secwatch.observer/filing/0000950103-25-013103.json
- Plain text: https://secwatch.observer/filing/0000950103-25-013103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.